Assistant Professor KASHIWA, Munenobu
Faculty, Affiliation
Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences
College and School Educational Field
Laboratory
Academic Background
Career
Year & Month of Birth
Academic Society
Award
Specialities
Speciality Keywords
Health technology assessment Cost-effectiveness analysis
Research Themes
Books
Papers
- Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. Munenobu Kashiwa,Ryo Matsushita Clinical therapeutics 42 7 1361 2020/07
- Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan. Munenobu Kashiwa,Ryo Matsushita Clinical therapeutics 41 5 929 2019/05
- Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer Munenobu Kashiwa,Ryo Matsushita International Journal of Clinical Pharmacy 2023/04/20
- Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan. Munenobu Kashiwa,Ryo Matsushita Biological & pharmaceutical bulletin 45 7 895 2022
- Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan. Munenobu Kashiwa,Ryo Matsushita Journal of pharmaceutical health care and sciences 7 1 35 2021/10/01
- Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan. Munenobu Kashiwa,Ryo Matsushita Clinical therapeutics 42 7 1376 2020/07
- Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan. Munenobu Kashiwa,Ryo Matsushita BMC health services research 19 1 438 2019/07/01
- Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan. Munenobu Kashiwa The European journal of health economics : HEPAC : health economics in prevention and care 2023/06/01
Conference Presentations
Others
Arts and Fieldwork
Patent
Theme to the desired joint research
Grant-in-Aid for Scientific Research
○「進行胃癌に対する抗がん剤選択効率化のための医療経済評価研究」(2022-2024)
Competitive research funding,Contribution
Collaborative research,Consignment study
Classes (Bachelors)
○Pharmacoepidemiology(2023)
○Case Coference in a Variety of Clinical Settings(2023)
○Case Coference in a Variety of Clinical Settings(2023)
○Introduction to Data Science(2023)
○Pharmacy Practice 2(2022)
○Introduction to Data Science(2022)
○Pharmacy Practice 4(2022)
○Pharmacy Practice 3(2022)
○Clinical Pharmacy Practice(2022)
○Pharmacy Practice 2(2022)
○Pharmacy Practice 3(2022)
○Pharmacy Practice 3(2022)
○Pharmacy Practice 2(2022)
○Pharmacy Practice 2(2022)
○Pharmacy Practice 4(2022)
○Clinical Pharmacy Practice(2022)
○Clinical Pharmacy Practice(2022)
○Pharmacy Practice 4(2022)
○Pharmacoepidemiology(2022)
○Pharmacoepidemiology(2022)
○Pharmacy Practice 3(2022)
○Pharmacy Practice 4(2022)
○Clinical Pharmacy Practice(2022)